تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
19.1848 US$
−0.8352 US$ · -4.17%
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
أحدث البيانات المتاحة
19.1848 US$
−0.8352 US$ · -4.17%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
40
مرتفع السعر
المشاعر
62
صعودي
المخاطر
50
مخاطر أعلى من المعتاد
الزخم
63
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
48.83 US$
ارتفاع محتمل بنسبة 154.52%صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Biotechnology ETFIBB7.94 مليون0.07%10.82 مليار USD0.44%201.55 US$-1.33%
AdvisorShares Psychedelics ETFPSIL1.84 مليون4.03%45.74 مليون USD1.84%20.63 US$-2.92%
iShares MSCI Ireland ETFEIRL1.06 مليون1.41%74.6 مليون USD0.50%79.59 US$+1.31%
Virtus Biotech Clinical Trials ETFBBC317.18 ألف0.76%41.91 مليون USD0.65%41.7699 US$-2.99%
Invesco Nasdaq Biotechnology ETFIBBQ107.98 ألف0.10%111.67 مليون USD0.19%33.73 US$-1.51%
ProShares Ultra Nasdaq BiotechnologyBIB52.79 ألف0.06%91.39 مليون USD1.19%105.55 US$-2.98%
First Trust IPOX Europe Equity Opportunities ETFFPXE11.04 ألف0.23%4.73 مليون USD0.70%31.44 US$-0.10%iShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILiShares MSCI Ireland ETFEIRLVirtus Biotech Clinical Trials ETFBBCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBFirst Trust IPOX Europe Equity Opportunities ETFFPXEالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
